Back to Annual Meeting Page		American Public Health Association 133rd Annual Meeting & Exposition December 10-14, 2005 Philadelphia, PA

Abstract #118550

Gary A. Richwald, MD,, MPH, Former Director, Los Angeles County STD Clinic, 250 Fifth Ave, Venice, CA 90291, 310-396-2200, drgary1@comcast.net, Charles Ebel, Senior Director, Program Development, American Social Health Association (ASHA), P.O. Box 13827, Research Triangle Park, NC 27709, Terri Warren, RN, MS, ANP, Westover Heights Clinic, 2330 NW Flanders Street, Suite 207, Portland, OR 97210, and Barry Bleidt, PhD, PharmD, Professor and Associate Dean, Academic Affairs, Irma Lerma Rangel College of Pharmacy, Texas A&M University-Kingsville, MSC 131, 700 University Blvd., Kingsville, TX 78363-8202.

The wider availability of new HSV-2 & 1 blood tests have dramatically improved the diagnosis of genital herpes, the most prevalent STD in the US with over 50 million infected. Newly available serologic tests that are accurate and type-specific have made it possible to identify infected individuals without genital lesions and those with mild, unrecognized symptoms. Since infected individuals often shed virus asymptomatically and [or?] may have lower genital tract inflammation attributable to other causes, the implications for improved clinical care and prevention of transmission are significant. This new technology, however, raises questions of whom to test, how to interpret results, and how to counsel and manage patients. In this seminar, experts will discuss the latest thinking on these topics.

Learning Objectives:

• See abstract.

Presenting author's disclosure statement:

I wish to disclose that I have NO financial interests or other relationship with the manufactures of commercial products, suppliers of commercial services or commertial supporters WITH THE EXCEPTION OF Grants received from and member of the speakers Bureau for GlaxoSmithKline..